On November 6, 2026, the 24th Mediterranean Arc Oncology Meeting (XXIV Jornada del Arco Mediterráneo) was held in Barcelona, Spain. Shi Yuanyuan, Chairman of the Cell Valley Group, was invited to attend the meeting online and delivered a keynote speech titled "Development Pathway for Oncology Drugs and Key Regulatory Standards in China and Differences vs FDA/EMA," sharing professional insights on China's oncology drug R&D and regulatory registration system, and engaging in academic exchange with international experts in the field of oncology medicine.

The Mediterranean Arc Oncology Meeting is hosted by ACROSS (Associació Catalana per la Recerca Oncològica i les Seves Implicacions Sanitàries i Socials), an annual professional academic conference in oncology. ACROSS is a Spanish oncology professional organization with a long history and academic accumulation, founded in 1999 and headquartered in Barcelona. The association brings together experts and scholars from multidisciplinary fields including medical oncology, surgical oncology, basic medicine, and pharmacy, and has long been committed to advancing basic and clinical oncology research, the exchange of innovative therapeutic technologies, and the improvement of comprehensive diagnosis and treatment standards for oncology patients. Its "Mediterranean Arc Oncology Meeting" has been held for more than twenty consecutive sessions and is an oncology academic exchange platform with sustained influence in Catalonia, Spain, and the Mediterranean coastal region, providing important professional exchange opportunities for precision oncology, immunotherapy, and clinical translation research. The association currently has over 300 affiliated members, covering multiple professional fields including medical oncology, surgical oncology, pathology, and radiology. This year's meeting focused on emerging immunotherapy topics in the oncology field, aiming to promote knowledge exchange and collaboration among different medical specialties and advance the continuous development of oncology research, clinical practice, and diagnosis and treatment standards.

At this meeting, Professor Shi Yuanyuan delivered a keynote speech on China's oncology drug development pathway and key regulatory standards, focusing on the main processes of oncology drugs in China from R&D, clinical trials to regulatory registration and marketing review. He also systematically compared the characteristics and differences in drug development pathways, clinical trial management, registration review requirements, and regulatory standards across different regions, in conjunction with the relevant regulatory systems of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Following the speech, the meeting chair and participating experts engaged in a 20-minute Q&A interaction with Professor Shi Yuanyuan.

The speech, grounded in China's pharmaceutical industry development and international regulatory practice, helped international attendees further understand the basic framework of China's oncology drug R&D and regulatory system, while providing a professional perspective for the exchange of experience in drug R&D, clinical research, and regulatory registration across different countries and regions. Through the comparison and analysis of the regulatory systems of China, the United States, and Europe, the meeting further promoted international understanding in the oncology pharmaceutical field of different regulatory environments, R&D requirements, and clinical translation pathways, providing a useful reference for cross-regional pharmaceutical R&D cooperation and international development.

This invitation to attend the meeting reflects the international academic community's attention to China's oncology pharmaceutical development and professional exchange. Going forward, the Cell Valley Group will continue to deepen international exchange and cooperation, promote the alignment of innovative pharmaceutical technologies and clinical translation with international standards, and work with global partners to explore innovative pathways in oncology treatment, creating more treatment possibilities for oncology patients worldwide.